Teva sales in North America fall

May 11, 2011 12:25


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries Ltd. reported revenue of $4.1 billion in the first quarter of 2011, 12 percent up from the corresponding quarter of 2010. Sales in North America were $2.064 billion in the first quarter, 11% lower than the corresponding quarter.

Revenue for the first quarter was below the consensus of 20 top Wall Street analysts who had predicted revenue of $4.25 billion.

However, non-GAAP net profit of $936 million in the first quarter, up 13% from the corresponding quarter, did meet analysts' expectations. Earnings per share were up 14% to $1.04.

Related Content

Breaking news
August 16, 2018
UNRWA says schools for Palestinians to open despite U.S. funding cut